This study is looking into whether semaglutide, a medicine already approved for diabetes and obesity, can be safely used by people with advanced lung diseases like interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease (COPD), or pulmonary hypertension. The main goal is to see if patients can tolerate semaglutide and if the dosage can be adjusted to help with weight management. You would receive semaglutide by injection once a week for 12 weeks. Researchers will check your lung function, physical ability, and body composition before and after treatment, and you'll report any side effects. This study is for adults aged 18 to 80 who have one of these lung conditions, a BMI (body mass index) over 30, and need oxygen when active. You cannot participate if you have diabetes, are pregnant, or breastfeeding.

Study design

This is a small, open-label pilot study involving 8 adult participants. It is an interventional study, meaning participants will receive a specific treatment.

What's involved

You would receive once-weekly injections of semaglutide for 12 weeks. You will also undergo pulmonary function, physical function, and body composition tests, and have blood drawn before and after the 12-week treatment period.

Compensation

Not stated in the trial record.

Follow-up

Participants will be monitored for 12 weeks while receiving semaglutide therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.